Impact of Sars-CoV-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with B-cell malignancies: a single-center retrospective study. Mediterr J Hematol Infect Dis [Internet]. 2023 Oct. 30 [cited 2026 Apr. 30];15(1):e2023061. Available from: https://www.mjhid.org/mjhid/article/view/5415